๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Eli Lilly and Company
Phase 1
677
Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi'an, Zhejiang
2023-01-12
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677Systemic Lupus Erythematosus
Bristol-Myers Squibb
Phase 3
516
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Baoding, Luoyang, Zhengzhou
2023-01-12
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo
Phase 3
1,170
Beijing, Beijing Sheng, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-01-11
Recruiting
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
NCT05615974Malignant Tumors
LaNova Medicines Limited
Phase 1/2
139
Guangzhou, Wuhan, Linyi, Beijing, Shanghai
2023-01-11
Active, closed
Compont - Varicose Veins of the Lower Extremities
NCT06387264Varicose Veins of Lower Limb
Peking University People's Hospital
Not applicable
188
Beijing
2023-01-11
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 3
606
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2023-01-10
Recruiting
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
NCT06230471Biliary Tract Neoplasms Immunotherapy
Peking Union Medical College Hospital
Phase 2
60
Beijing
2023-01-09
Active, closed
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
NCT05661955Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
BeiGene
Phase 1/2
113
Beijing, Fuzhou, Lanzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2023-01-09
Active, closed
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241IgG4 Related Disease
Zenas BioPharma (USA), LLC
Phase 3
194
Beijing, Shijiazhuang, Wuhai, Yantai, Shanghai, Taiyuan, Chengdu
2023-01-09
Active, closed
Adult Spinal Muscular Atrophy (SMA) China Registry
NCT05618379Muscular Atrophy, Spinal
Biogen
Observational
200
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Nanchang
2023-01-06
Recruiting
Transcranial Ultrasound Stimulation for Cognitive Function Modulation in Patients With Post COVID-19 Brain Fog
NCT07154199COVID-19, Brain Fog, Long COVID, Transcranial Ultrasound Stimulation
Xuanwu Hospital, Beijing
Not applicable
40
Beijing, Jining
2023-01-06
Recruiting
Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
NCT05717699Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event
Capital Medical University
Phase 1
18
Beijing
2023-01-04
Recruiting
Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
NCT05717712Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event
Capital Medical University
Phase 1
18
Beijing
2023-01-04
Recruiting
A Prospective, Multicenter, Randomized, No-treatment Controlled, Assessor-blinded, Superiority Clinical Trial to Evaluate the Efficacy and Safety of Polycaprolactone Gel for Injection to Improve Temple Hollowing in Chinese Adults
NCT06972940Temple Hollowing
AQTIS Medical B.V.
Not applicable
159
Beijing
2023-01-03
Recruiting
Prospective Cohort Study on Refractory Rheumatoid Arthritis
NCT07126431Rheumatoid Arthritis
Peking University Third Hospital
Observational
200
Beijing
2023-01-01
Active, closed
Key Technology Research and Application Demonstration of Individual Protective Equipment for High-Level Biosafety Laboratories
NCT06697379Biosafety Protection, Infectious Diseases
Minghui Li
Observational
100
Beijing
2023-01-01
Recruiting
Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge
NCT07453342Immune-Related Adverse Events
Peking Union Medical College Hospital
Observational
500
Beijing
2023-01-01
Recruiting
MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer
NCT07156058Biliary Tract Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
204
Beijing
2023-01-01
Recruiting
Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research
NCT06559761Hepatocellular Carcinoma Stage III
Chinese PLA General Hospital
Observational
500
Beijing
2023-01-01
Recruiting
The Impact of Preoperative Quantitative Flow Reserve (QFR) on Early Postoperative Radial Artery Graft Outcomes in Coronary Artery Bypass Grafting
NCT07669987Quantitative Flow Reserve, Minimally Invasive Coronary Surgery, Radial Artery
Peking University Third Hospital
Observational
110
Beijing
2023-01-01
Recruiting
Clinical Study on the Treatment of Pelvic Pain With Wearable Dual-band LED Device
NCT06982989Pelvic Pain
Peking University Third Hospital
Not applicable
250
Beijing
2023-01-01
Recruiting
Feedback Loop Between Intracranial Atherosclerosis and Cerebral Small Vessel Disease
NCT05677607ICAS - Intracranial Atherosclerosis, Cerebral Small Vessel Diseases
Chinese PLA General Hospital
Observational
300
Beijing
2023-01-01
Recruiting
Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation
NCT05638841Atrial Fibrillation
Peking University Third Hospital
Observational
300
Beijing
2023-01-01
Recruiting
The Clinical Study of 3D-printed Magnesium Alloy Prosthesis With Controllable Degradation Rate in the Repair of Periarticular Bone Defects
NCT06349629Degradation of Magnesium Alloy Prosthesis and New Bone Regeneration
Peking University Third Hospital
Not applicable
60
Beijing
2023-01-01
Recruiting
Retzius-sparing Robot-assisted Radical Prostatectomy With "Sandwich" Technique of Total Urethral Reconstruction Versus Standard Robot-Assisted Radical Prostatectomy Versus Laparoscopic Radical Prostatectomy Surgery: A Comparative Prospective Study of 300 Patients
NCT06730243Retzius-sparing Robot-assisted Radical Prostatectomy With "Sandwich" Technique of Total Urethral Reconstruction
Ministry of Science and Technology of the Peopleยดs Republic of China
Not applicable
300
Beijing
2023-01-01
By invitation
Does Medial Raw Anchor Necessary During Tendon Repair Combined With Microfracture
NCT06431191Full Rotator Cuff Tear, Microfracture Procedure, Double Raw Repair, Lateral Raw Repair
Beijing Jishuitan Hospital
Not applicable
50
Beijing
2023-01-01
Recruiting
The Cohort Study for Asthma in China
NCT05937334Asthma, Bronchial
Beijing Chao Yang Hospital
Observational
400
Beijing
2023-01-01
Recruiting
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
NCT05603559Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase EARLY_PHASE1
30
Beijing
2023-01-01
Recruiting
The Relationship Between Brain Injury Biomarkers in Cerebrospinal Fluid and Blood of Patients After Cardiac Arrest and Prognosis
NCT06624488Cardiac Arrest (CA), Brain Injuries, Acute
Tang Ziren
Observational
30
Beijing
2023-01-01
Recruiting
Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia
NCT06802718Acute Myeloid Leukemia
Peking University People's Hospital
Phase 3
96
Beijing
2023-01-01
Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275Gastric Cancer, Peritoneal Metastases
Chinese Academy of Sciences
Observational
400
Beijing, Fuzhou, Guangzhou, Guiyang, Kunming, Taiyuan, Zhengzhou, Zhenjiang
2023-01-01
Recruiting
Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion
NCT05589207Carcinoma, Renal Cell, Tumor Thrombus, Neoplasm Invasiveness, Inferior Vena Cava Interruption
Peking University Third Hospital
Observational
232
Beijing
2023-01-01
By invitation
Efficacy and Safety of Endovascular Thrombectomy in Acute Ischemic Stroke With Posterior Circulation Large Infarct
NCT06924996Acute Basilar Artery Occlusion, Posterior Circulation Large Infarct
Feng Gao
Observational
500
Beijing
2023-01-01
Active, closed
Investigation of Hemodynamics and Radiomics Based on High Resolution Magnetic Resonance Imaging for Predicting the Outcomes of Intracranial Dissecting Aneurysm
NCT07335029Cerebrovascular Disease, Intracranial Aneurysm, Intracranial Arterial Dissection
Beijing Neurosurgical Institute
Observational
208
Beijing
2023-01-01
Recruiting
AI-Driven Prediction of Dialysis Outcome With EHR
NCT06791447Dialysis Patients
The Eye Hospital of Wenzhou Medical University
Observational
1,000,000
Beijing
2023-01-01
Recruiting
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
NCT05672043Medulloblastoma, Central Nervous System Tumor, Pediatric, Ependymoma, Germ Cell Tumor
Beijing Tiantan Hospital
Observational
400
Beijing
2023-01-01
Not yet open
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
NCT05590572Osteosarcoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
148
Beijing, Jinan, Shanghai
2023-01
Not yet open
Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma
NCT05505461Adenocarcinoma of Esophagogastric Junction
Peking University People's Hospital
Phase 2
26
Beijing
2023-01
Recruiting
Research on Early Screening and Diagnosis of Pulmonary Nodules Based on Novel Non-invasive Technologies.
NCT07370077Lung Cancer
Chen KeZhong
Observational
1,800
Beijing
2022-12-31
Not yet open
A Clinical Trial of the Transcatheter Aortic Valve Implantation System With a Prospective, Multi-Center, One-Arm Approach to Evaluate the Efficacy and Safety in the Treatment of Patients With Severe Aortic Stenosis
NCT05673525Aortic Stenosis
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
131
Beijing
2022-12-30
Active, closed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642Chronic Obstructive Pulmonary Disease (COPD)
Hoffmann-La Roche
Phase 3
1,290
Guangzhou, Zhanjiang, Zunyi, Lianyungang, Beijing, Changchun, Changsha, Chengdu
2022-12-29
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.
Phase 3
2,500
Beijing, Lanzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changchun
2022-12-27
Recruiting
Phase 1 Trial of KH617
NCT05667194Advanced Solid Tumors
Sichuan Honghe Biotechnology Co., Ltd.
Phase 1
45
Beijing
2022-12-26
Active, closed
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526Alzheimer Disease
AriBio Co., Ltd.
Phase 3
1,535
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Heping, Nanchang
2022-12-23
Recruiting
Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort
NCT05862103Acute Myocardial Infarction, Adverse Event
Yu Bo
Observational
15,000
Beijing, Guangzhou, Nanning, Shijiazhuang, Daqing, Zhengzhou, Nanjing, Nanchang
2022-12-21
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
AstraZeneca
Phase 1
167
Beijing, Chongqing, Guangzhou, Wuhan
2022-12-21
Recruiting
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
NCT05749289SSTR Positive Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
400
Beijing
2022-12-20
Active, closed
TIME in Immunotherapy Combined With nCRT for Rectal Cancer
NCT05507112Locally Advanced Rectal Cancer
Peking Union Medical College Hospital
Phase 2
100
Beijing
2022-12-20
Recruiting
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
102
Beijing, Changchun, Jinan
2022-12-20
Active, closed
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
NCT05335876Spinal Muscular Atrophy (SMA)
Novartis Pharmaceuticals
Phase 3
20
Chongqing, Guangzhou, Chengdu, Beijing
2022-12-19
Active, closed
A Study Assessing Repathaยฎ in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
NCT06295679Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease
Amgen
Observational
7,000
Beijing, Chongqing, Dongguan, Foshan, Guangzhou, Huizhou, Zhuhai, Guilin
2022-12-19
Recruiting
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
NCT05652920Hepatocellular Carcinoma
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Recruiting
Thrombus Imaging and Treatment Analytics in Neurology
NCT05663281Thrombus, Brain, Thrombosis
Chinese PLA General Hospital
Observational
100
Beijing
2022-12-15
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
213
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Active, closed
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors
NCT05683353SARS-CoV-2 Infection, Hematologic Malignancy
Peking University First Hospital
Observational
60
Beijing
2022-12-14
Active, closed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303Atherosclerotic Cardiovascular Disease
Amgen
Phase 3
7,297
Beijing, Guangzhou, Huizhou, Nanning, Daqing, Harbin, Nanyang, Changsha
2022-12-14
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou
2022-12-13
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1/2
57
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang
2022-12-13
Active, closed
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988Non-small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 3
324
รœrรผmqi, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-12-13
Recruiting
Allogenic CD19-targeting CAR-ฮณฮดT Cell Therapy in R/R NHL
NCT05554939Non Hodgkin's Lymphoma
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2022-12-11
Active, closed
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Active, closed
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
NCT05263583High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Cothera Bioscience, Inc
Phase 2
14
Beijing, Guangzhou, Henan, Pudong, Tianjin, Wuhan
2022-12-09
Recruiting
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT05611801Hemophilia A, Hemophilia B
Pfizer
Phase 3
100
Beijing, Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin
2022-12-09
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Genmab
Phase 1/2
884
Beijing, Chongqing, Changsha, Nanchang, Changchun, Chengdu, Shanghai, Hangzhou
2022-12-07
Active, closed
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression โ‰ฅ 1% and an STK11 Co-mutation.
NCT05445843Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression โ‰ฅ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals
Phase 2
95
Wuhan, Changsha, Beijing
2022-12-06
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984Advanced Solid Tumors
AbbVie
Phase 1
288
Beijing, Wuhan, Shenyang, Shanghai
2022-12-05
Active, closed
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777Cough, Refractory Chronic Cough
Bellus Health Inc. - a GSK company
Phase 3
997
Kunshan, Leshan, รœrรผmqi, Beijing, Changsha, Chengdu, Chongqing, Dongguan
2022-12-05
Recruiting
A Study on Diagnosis and Treatment Strategies for Atlantoaxial Dislocation
NCT06233539Atlantoaxial Dislocation, Treatment, Diagnostic
Peking University Third Hospital
Observational
3,000
Beijing
2022-12-01
Recruiting
Deep Enhanced Imaging in Stroke and Vascular Neurology
NCT05614193Radiology, Cerebral Stroke, Vascular Diseases
Chinese PLA General Hospital
Observational
1,000
Beijing
2022-12-01
Recruiting
Intelligent Diagnosis and Treatment Model for Insomnia Disorder
NCT06375447Insomnia
Xuanwu Hospital, Beijing
Observational
16,000
Beijing, Changchun, Chengdu, Suzhou
2022-12-01
Recruiting
Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy
NCT05858983Biallelic RPE65 Mutation-associated Retinal Dystrophy
Frontera Therapeutics
Phase 1/2
9
Beijing
2022-11-30
Active, closed
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585Breast Cancer
AstraZeneca
Phase 3
1,174
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2022-11-28
Recruiting
Artificial Intelligence System for Early Warning of Adverse Events in Acute Myocardial Infarction
NCT07139860Acute Myocardial Infarction With ST Elevation, Intelligent Management Platform, Early Warning
Hui Chen
Observational
1,400
Beijing
2022-11-26
Active, closed
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104
NCT05476887Paroxysmal Nocturnal Hemoglobinuria
Kira Pharmacenticals (US), LLC.
Phase 2
35
Beijing, Nanjing, Tianjin, Zhengzhou
2022-11-25
Recruiting
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
NCT05410730High-risk NMIBC
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
150
Beijing
2022-11-23
Active, closed
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3
260
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Jinan, Qingdao
2022-11-21
Active, closed
Primary Cervical Cancer Screening by Self-sampling HPV Test
NCT05613283Human Papillomavirus Infection, Cervical Cancer, Negative For Intraepithelial Lesion Or Malignancy, Atypical Squamous Cells of Undetermined Significance
Peking University People's Hospital
Observational
17,875
Beijing, Zhengzhou, Changsha, Chengdu, Hangzhou
2022-11-19
Recruiting
C2 Esophageal Squamous Epithelium Dysplasia
NCT05349240Esophageal Squamous Epithelium Dysplasia
Pentax Medical
Not applicable
129
Beijing, Changchun, Changzhi, Shijiazhuang
2022-11-18
Recruiting
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
NCT05678270Intrahepatic Cholangiocarcinoma (ICC)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
70
Hefei, Beijing, Fujian, Fuzhou, Foshan, Guangzhou, Shijiazhuang, Harbin
2022-11-15
Recruiting
Study of ZGGS18 in Patients With Advanced Solid Tumors
NCT05584800Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
222
Beijing
2022-11-15
Active, closed
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
NCT05374603Lung Cancer
AstraZeneca
Phase 2
47
Beijing, Changsha, Chongqing, Hangzhou, Jinan, Kunming, Nanchang, Ningbo
2022-11-15
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
Pfizer
Phase 3
1,116
Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai
2022-11-10
Active, closed
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227Eosinophilic Esophagitis
AstraZeneca
Phase 3
368
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
2022-11-10
Recruiting
A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease
NCT05970783Chronic Pelvic Pain
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 3
414
Beijing
2022-11-08
Active, closed
A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion
NCT05615038Basilar Artery Occlusion, Endovascular Treatment
Beijing Tiantan Hospital
Not applicable
338
Hefei, Beijing, Anyang, Zhangzhou, Baotou
2022-11-07
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05614102Advanced Solid Tumors
Bayer
Phase 1
284
Beijing, Shenzhen, Hangzhou
2022-11-04
Recruiting
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer
NCT05529615Colon Cancer, Circulating Tumor DNA
Peking University Cancer Hospital & Institute
Not applicable
2,684
Beijing
2022-11-01
Not yet open
Implantable Vagus Nerve Stimulation Modulation of Coeruleus-Norepinephrine Network for Mild-Moderate AD Patients
NCT05575271Alzheimer Disease
Xuanwu Hospital, Beijing
Not applicable
6
Beijing
2022-11-01
Active, closed
Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC
NCT05951127Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
141
Beijing
2022-11-01
By invitation
Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma
NCT05844813Retroperitoneal Sarcoma
Peking University International Hospital
Phase 4
102
Beijing, Qingdao, Shanghai, Xiโ€™an
2022-11-01
Recruiting
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
NCT06595186Glioblastoma Multiforme (GBM)
JenKem Technology Co., Ltd.
Phase 2
25
Beijing
2022-10-31
Recruiting
Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
NCT05909436Solid Tumor
Guangzhou Gloria Biosciences Co., Ltd.
Phase 1/2
107
Beijing
2022-10-31
Recruiting
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
NCT07231068Non-Small Cell Lung Cancer
Henan Genuine Biotech Co., Ltd.
Phase 1/2
153
Beijing, Guangzhou, Zhengzhou
2022-10-31
Active, closed
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
NCT05522231Advanced Renal Cell Carcinoma
Hutchmed
Phase 2/3
265
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2022-10-27
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
Novartis Pharmaceuticals
Phase 1
126
Guangzhou, Beijing
2022-10-26
Recruiting
Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
NCT05377034Locally Advanced Hepatocellular Carcinoma
National Cancer Centre, Singapore
Phase 2
100
Beijing, Chengdu, Jinan
2022-10-26
Recruiting
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
NCT05458219Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
470
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha
2022-10-26
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
Beijing, Shanghai
2022-10-25
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou
2022-10-25
Rows per page Showing 4401–4500 of 5484
Previous 43 44 45 46 47 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=45

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.